Cervical Cancer 8/20/2008. New genital HPV infections are commonest amongst young adults. Development of antibody to HPV capsids after HPV infection
|
|
- Lucas Lewis
- 5 years ago
- Views:
Transcription
1 Preventing cervical cancer from bench to bedside and beyond Ian Frazer Diamantina Institute, The University of Queensland, Brisbane, Australia Cervical Cancer Second commonest cause of cancer in women worldwide.25m deaths/year >99.8% attributable to HPV infection Two HPV types (16 and 18) responsible for >7% of cancers HPV Infection is very common (>3%) only rarely leads to cancer (<2%) 15 year lag period between infection and cancer Cervical Cancer : the HPV connection 4 main groups: % % % % + HPV X 85.% % % % % % % nital Warts on-years Rate of New Ge per 1 Perso New genital HPV infections are commonest amongst young adults Incidence of New Genital Warts in Women by Age in US < Age (years) Insinga RP. Clin Inf Dis. 23;36: High risk HPVs and Tonsillar Cancer.3.6 S MR 1 2 S MR MALES FEMALES HPV in tonsillar Cancer Age group HPV+ve HPV -ve Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer Lalle Hammarstedt, David Lindquist, Hanna Dahlstrand, Mircea Romanitan, Liselotte Dahlgren, Jeanna Joneberg, Nomi Creson, Johan Lindholm, Weimin Ye, Tina Dalianis and Eva Munck-Wikland Int. J. Cancer: 119, (26) Development of antibody to HPV capsids after HPV infection Proportion of wom men seroconverted HPV 6 HPV 16 HPV Months since first HPV DNA detected Capsid specific antibody is: - not a diagnostic test for HPV - not a marker for likely regression Carter JJ et al J Infect Dis 2, 181,
2 Serum antibody to VLP conformational determinants conveys protection s to prevent HPV infection Zur Hausen Serum from dogs from group 6 (control) and 4 (immunised), transferred to groups of naïve animals, challenged with COPV. OUTCOME: Group 6: 4/4 with warts; Group 4: /4 with warts Cancer associated Human (~198) -Some HPVs cause cancer - Virus can t be grown in the lab Jian Zhou Virus Like particles 1 (~199) - L1 recombinant DNA - Self assembly to VLPs - VLPs highly immunogenic J. A. Suzich, S. J. Ghim, F. J. Palmer-Hill, W. I. White, J. K. Tamura, J. A. Bell, J. A. Newsome, A. B. Jenson, and R. Schlegel.. Proc.Natl.Acad.Sci.U.S.A 92 (25): , :J. Zhou, X. Y. Sun, D. J. Stenzel, and I. H. Frazer. Virology 185 (1): , Clinical Lesion Virus L1 gene L1 + Expression Vector Eukaryotic Cell Gene expression s to prevent HPV infection Zur Hausen Expression Vector Gene cloning Virus Like particle purification Cancer associated Human (~198) -Some HPVs cause cancer - Virus can t be grown in the lab Jian Zhou Virus Like particles 1 (~199) - L1 recombinant DNA - Self assembly to VLPs - VLPs highly immunogenic HPV vaccines (~25) -Conventional vaccines - VLPs+ adjuvant - Neutralising Antibody Clinical trial validation ALUM Addition of adjuvant 1:J. Zhou, X. Y. Sun, D. J. Stenzel, and I. H. Frazer. Virology 185 (1): , Protection > 5yrs - Safe Disclosure of conflict of interest HPV vaccines One technology two products Dr Ian Frazer and the University of Queensland benefit financially from commercial sale of the prophylactic HPV vaccines discussed in this talk Gardasil Manufacturer Merck (CSL) GSK Cervarix HPV types 6,11,16,18 16,18 Adjuvant Proprietary Alum Alum OH +MPL (ASO4) Administration,2,6 months,1,6 months Manufacture Yeast SF9 cells/baculovirus 2
3 HPV 16/18-Related Cervical Cancer Efficacy Quadrivalent vaccine Mean 36 Months of Follow-Up Subjects = Women, without prior infection with vaccine HPV types Efficacy = Prevention of disease caused by vaccine HPV types High grade anogenital lesion (CIN, AIN) Cases Cases (N=9342) (N=94) Efficacy 95% CI (92, 1) HPV vaccine Phase III trial outcomes Study 1 2 No of subjects End-points efficacy Control % (confidence limits) Koutsky 6/11/16/ CIN 2/3 AIS 98 (86-1) Ault 6/11/16/ CIN 2/3 AIS 99 (93-1) Garland 6/11/16/18 Joura 6/11/16/18 Harper 16/ Parvonen 16/ CIN 2/3 AIS 1 (94-1) GW VIN VAIN 1 (94-1) VIN2/3 VAIN 2/3 CIN CIN2,3 CIN CIN2,3 1 (72-1) 1 (42-1) 1 (-8-1) 89 (59-99) 9 (53-99) Adapted from J. A. Kahn and R. D. Burk. Papillomavirus vaccines in perspective. Lancet 369 (958): , 27. Efficacy Against HPV 6/11/16/18- Related External Genital Lesions Mean 32 Months of Follow-Up Cases (N = 7899) Cases (N = 7897) Efficacy CI EGL , 1 Cross protection against HPV associated CIN 2/3 CIN 2/3 CASES N= 4675 %Efficacy (95% CI) caused by N= 4616 any HPV (24,62) types 52 1 (93,1) Non vaccine types (6, 6) Non vaccine A9 (HPV16 like) (1, 68) Non vaccine A7 (HPV18 like) (-35, 8) Protection over time against CIN2/3 -all HPV types Percent t CIN 2/3 1 cerv /1 vical treatment avoided women/year Months A 7% reduction in cervical pre-cancer is observed with vaccination Despite some cross protection there is still residual disease due to non vaccine HPV types Source : ACIP website 28/3/3 3
4 HPV VACCINE FAQs Are there vaccine specific side effects? (Data for Quadrivalent vaccine) controlled trials Injection Site (1 to 5 days Postvaccination) Post Marketing surveillance 22,, doses over 12 months (Aluminum) (Saline) (N=5,88) (N=3,47) (N=32) 7526 reported possibly associated events (June 8) Pain 83.9% 75.4% 48.6% Mostly nonserious -fainting 11 (one broken nose) Swelling 25.4% 15.8% 7.3% Urticaria (5) Anaphylaxis (28) Erythema 24.6% 18.4% 12.1% Some serious events 3 cases Guillain Barre?expected fqy Pruritus 3.1% 2.8%.6% Systemic AEs (1 to 15 days Postvaccination) 1244 Pregnancies in vaccine group (N=5,88) (N=3,79) 1272 Pregnancies in placebo group Fever 1.3% 8.6% Nausea 3.6% adverse events in vaccine 4.2% group and placebo 4.1% group Dizziness 15 (vaccine) and 16 (placebo) congenital 2.8% abnormalities 2.6% What about pregnancy safety? Neutralizing Antibodies By Age at Enrollment 1 Neutralizing anti-hpv 6 GMTs at month 7 T with 95% U/mL Serum clia GM CI, mmu Block SL, Nolan T, Sattler C, et al. 26 Immunogenicity Bridge Efficacy Program Up to 1% clinical protection Adolescent Males + Females Females Only Age at Enrollment (Years) Month 7 Anti-HPV Neutralizing GMTs By Age Category Per-Protocol Immunogenicity Population* Anti-HPV 6 Anti-HPV Anti-HPV 16 Anti-HPV NOTE: non-logarithmic axes. *Subjects who were not general protocol violators, received all three doses within acceptable day ranges, were seronegative at day 1 and PCR negative day 1-month 7 for all relevant HPV types, and had a month 7 serum sample collected within an acceptable day range. Subjects years of age are from prior analyses and are included for comparison Primary Efficacy Results (young and younger women) Combined Incidence of HPV 6/11/16/18-Related Persistent Infection or Cervical/Vulvar/Vaginal Disease Per Protocol Efficacy Population Population Efficacy 95% CI P-value P19 Mid-Adult Women % 74, 98 <.11 P7 Young-Adult % 78, 1 <.1 Women P19: 24- to 45-Year- Women; mean of 1.65 years follow-up P7: 16- to 23-Year- Women; mean of 2.33 years follow-up* Antibody Titer Geometric Mean A (Log Scale) Anti HPV-16 Antibody over 5 years. 1 ) ** * Time Since Vaccination 1 (Months) Natural infection) Protection persists at 5 Years HPV 6, 11, 16, or 18-Related Persistent Infection N Cases N Cases Efficacy (%) 95% CI 235 2* Disease CIN 1, 2, or < 1 Vulvar/vaginal neoplasias or genital warts < 1 Per Protocol efficacy against vaccine HPV types. 4
5 Papillomavirus Prophylactic s Where Next? Determine from ongoing studies Duration of protection Scandinavian Cohort study Efficacy in men Significance of cross protection Efficacy in older women Studies underway Consider broader spectrum vaccines Challenge how do you prove efficacy, if you need 25, subjects to do it, and have no approved surrogate marker deployment Licenced in over 8 countries Mostly for males and females USA, Malaysia, Canada females only Government sponsored univesal immunisation programs (routine + catch-up) in: Australia (Quadrivalent) (Girls ) Commenced April 27 through schools and GPs - 8% coverage in schools in most states Germany, Italy, France (Q), Canada(Q), Great Britain (B) (Girls ) to commence in 28 Developing world initiatives Gates Foundation, Merck/GSK, WHO collaborating on delivery to countries with GDP < US$1 Field trials delivery strategies (eg Vanuatu) underway Deploying vaccines in the developing world >1% of healthy Vanuatu Women over 3 have CIN3 No screening program feasible one part time gynae for.2m people >5% of 12 year old girls no longer attend school Challenge how to fund and how to deliver vaccine. Conclusions s to prevent cervical cancer are here! They can prevent, with best results from early universal immunisation Up to 7% of cervical cancer in an unscreened population The majority of abnormal pap smears in screened populations >9% of genital warts quadrivalent vaccine only (nb: no efficacy data for males yet) They are not therapeutic for existing infection, therefore full public health benefit requires universal administration to pre-teen girls individual women of any age may benefit. Vaccination should not alter participation in existing cervical cancer screening programs We cannot claim a job well done till vaccine is delivered in the developing world. 5
Prophylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More informationAn update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016
An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts
More informationWhat is the Safety and Efficacy of Vaccinating the Male Gender to Prevent HPV Related Neoplastic Disorders in Both the Male and Female Genders
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 What is the Safety and Efficacy of Vaccinating
More informationPRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant]
PRODUCT INFORMATION GARDASIL 9 [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] DESCRIPTION GARDASIL 9 *, Human Papillomavirus 9-valent Vaccine, Recombinant,
More informationClinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years
Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years Gudrun Maechler Director, Clinical & Medical Affairs Europe & Cervarix GSK Biologicals Presentation Outline HPV immunology Immunogenicity
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationPresenter Disclosure Information
1:30 2:25pm An Update on HPV Cancer Prevention SPEAKERS Kenneth Alexander, MD, PhD Anna Giuliano, PhD Presenter Disclosure Information The following relationships exist related to this presentation: Dr
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Silgard, suspension for injection. Silgard, suspension for injection in a pre-filled syringe. Human Papillomavirus Vaccine
More informationProfessor Margaret Stanley
19 th Annual Conference of the British HIV Association (BHIVA) Professor Margaret Stanley University of Cambridge 16-19 April 2013, Manchester Central Convention Complex 19 th Annual Conference of the
More informationHUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER
HUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER Virology The Human Papillomavirus (HPV) is a relatively small virus, belonging to the family Papillomaviridae, containing circular double-stranded DNA
More informationPrevention strategies against the human papillomavirus: The effectiveness of vaccination
Available online at www.sciencedirect.com Gynecologic Oncology 107 (2007) S19 S23 www.elsevier.com/locate/ygyno Prevention strategies against the human papillomavirus: The effectiveness of vaccination
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Gardasil, suspension for injection. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed). 2. QUALITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Gardasil, suspension for injection. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed). 2. QUALITATIVE
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1 PRODUCT NAME GARDASIL 9 Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human papillomavirus
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationMedia Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)
News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's
More informationFollowing microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells
Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells Virion Assembled Virus Stratified squamous epithelium Virion Suprabasal cells HPV DNA replication
More informationHPV Vaccine Ina Park, MD, MS
HPV Vaccine Ina Park, MD, MS California Department of Public Health STD Control Branch Alameda County Immunization Update 2014 Over 170 types of HPV classified Updated incidence/prevalence estimates (CDC):
More informationQuick Reference: Immunization Communication Tool For Immunizers HPV 2010
Quick Reference: Immunization Communication Tool For Immunizers HPV 2010 Are young girls being used as guinea pigs for an unproven vaccine? Client knowledge NO. In both clinical trials conducted for the
More informationGardasil, suspension for injection. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed). 20 micrograms.
1. NAME OF THE MEDICINAL PRODUCT Gardasil, suspension for injection. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed). 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5
More informationCommonly asked questions on human papillomavirus vaccine
Hong Kong J. Dermatol. Venereol. (2008) 16, 12-17 Review Article Commonly asked questions on human papillomavirus vaccine PKS Chan Recently, human papillomavirus (HPV) vaccine has been attracting the attention
More informationThe HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland
The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland Immunisations Very cost effective intervention Give vaccine before exposure to disease UK has life course approach
More informationThe Global Burden of HPV Related Cancers and Their Prevention
The Global Burden of HPV Related Cancers and Their Prevention What Every Doctor Should Know! Dr. Adrian Lear, MD Conflict of Interest Disclosure I have no financial relations with any commercial entity
More informationFossilised knowledge? Libraries as repositories of knowledge in biomedical research in the cyberspace era.
Fossilised knowledge? Libraries as repositories of knowledge in biomedical research in the cyberspace era. Ian Frazer Diamantina Institute, The University of Queensland, Brisbane, Australia i.frazer@uq.edu.au
More informationMEDICAL ADVISOR REPORT TT /1
I.1 Type NMA (abbreviated) MEDICAL ADVISOR REPORT TT50-7571/1 I.2 Medication Gardasil; Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine. The HPV vaccine is an aluminium adjuvanted
More informationThe successful case of HPV prophylactic vaccines
7th LA Congress of Clinical Research São Paulo, November 12, 2010 Brazilian Experience on Translational Medicine: The successful case of HPV prophylactic vaccines Luisa Lina Villa, Ph.D. Ludwig Institute
More informationQuadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil Ò )
ADIS DRUG EVALUATION Drugs 2010; 70 (18): 2449-2474 0012-6667/10/0018-2449/$55.55/0 ª 2010 Adis Data Information BV. All rights reserved. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationPreventing human papillomavirus (HPV) cancers and diseases by vaccination
Preventing human papillomavirus (HPV) cancers and diseases by vaccination Helping to protect young people from a range of cancers and diseases caused by the human papillomavirus (HPV) health.gov.au/immunisation
More informationLECTURE: human papilloma virus vaccine
LECTURE: human papilloma virus vaccine Editing File Important Doctor s notes Extra explanation Only F or only M وتقال هذه الجملة إذا "ال حول وال قوة إال باهلل العلي العظيم ".داهم اإلنسان أمر عظيم ال يستطيعه
More informationReceived 12 November 2010/Returned for modification 2 December 2010/Accepted 7 January 2011
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2011, p. 418 423 Vol. 18, No. 3 1556-6811/11/$12.00 doi:10.1128/cvi.00489-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Human Papillomavirus
More informationHPV Vaccines: Background and Current Status
HPV Vaccines: Background and Current Status Bogota, Colombia, 2007 Jon Kim Andrus, MD HPV and Cervical Cancer Evidence that HPV is essential: Documented molecular studies of cervical cancer Case-control
More informationHuman papillomavirus and vaccination for cervical cancer
Human papillomavirus and vaccination for cervical cancer Dorothy Machalek Department of Microbiology and Infectious Diseases Royal Women s Hospital, Melbourne, Australia VIRUSES AND CANCER Responsible
More informationGARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]
` Page 1 of 17 PRODUCT CIRCULAR GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] I. THERAPEUTIC CLASS GARDASIL is a recombinant, quadrivalent vaccine that protects
More information2 HPV E1,E2,E4,E5,E6,E7 L1,L2 E6,E7 HPV HPV. Ciuffo Shope Jablonska HPV Zur Hausen HPV HPV16. HPV-genome.
58 2 pp.155-164 2008 2. HPV 20 HPV HPV HPV HPV HPV L1 HPV-DNA 16/18 2 HPV16 /18 6/11 4 2 100 1 Ciuffo 1907 20 Shope 1933 Raus 1934 20 70 Jablonska HPV Orth HPV5 8 1983 zur Hausen HPV16 1 HPV-genome 920-8641
More informationPreventive Vaccines against HPV. Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin
Preventive Vaccines against HPV Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin Content 1. HPV associated diseases 2. Preventivevaccines Efficacy Safety
More informationVRBPAC Briefing Document for the Vaccines and Related Biological Products Advisory Committee (VRBPAC)
Food and Drug Administration Center for Biologics Evaluation and Research Office of Vaccines Research and Review Division of Vaccines and Related Product Applications VRBPAC Briefing Document for the Vaccines
More informationCrisis in US Health Care Failure of Primary HPV related Cancer Prevention. Learning Objectives. 4. Encourage the use the HPV vaccine
Crisis in US Health Care Failure of Primary HPV related Cancer Prevention Daron G. Ferris, MD Professor Department of Obstetrics and Gynecology Georgia Regents University Cancer Center Georgia Regents
More informationGARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine]
GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine] Fulfills Part A of the WHO Guidelines for Recombinant Human Papillomavirus Virus-like Particle Vaccines DESCRIPTION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationWho Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection?
CERVICAL CANCER REVIEW Who Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection? Jorma Paavonen, MD, Department of Obstetrics and Gynecology, Helsinki University Hospital, Haartmaninkatu
More informationInnovations in Human Papillomavirus Vaccine
Oct 2014 Life Health Innovations in Human Papillomavirus Vaccine Innovation 1 Topics 1. Current HPV vaccines 2. New development 3. What s next? 2 PART I CURRENT HPV VACCINES 3 Worldwide incidence of cervical
More information9/11/2018. HPV Yoga. Human Papillomavirus. Human Papillomavirus (HPV) Disease. Most common sexually transmitted infection in the U.S.
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Human Papillomavirus September 2018 Chapter 11 Photographs and images included in this presentation
More informationCervical Cancer Screening - Improving PAP Rates. Objectives
Cervical Cancer Screening - Improving PAP Rates Dineo Khabele, MD, FACOG, FACS Assistant Professor Division of Gynecologic Oncology Vanderbilt University Medical Center Objectives 1. Review the current
More informationPRODUCT CIRCULAR. GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]
PRODUCT CIRCULAR [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] I. THERAPEUTIC CLASS GARDASIL is a recombinant, quadrivalent vaccine that protects against Human Papillomavirus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary Dose Schedule 2. 9HPV vaccine 3. Primary HPV screening 4. Male vaccination 5. Update on Australia 6. Natural History 7.
Summary 1. 2 Dose Schedule 2. 9HPV vaccine 3. Primary HPV screening 4. Male vaccination 5. Update on Australia 6. Natural History 7. OPC and Anal 2 dose schedules The train has left the station 2 dose
More informationLo screening come setting per la vaccinazione (nelle donne non vaccinate in età target e nelle donne trattate) Silvia Franceschi
Lo screening come setting per la vaccinazione (nelle donne non vaccinate in età target e nelle donne trattate) Silvia Franceschi CONVEGNO NAZIONALE GISCi 2017 Ferrara 15---16 Giugno 2017 Secondary use/benefits
More informationAdolescent Immunizations
Adolescent Immunizations Preteen Vaccine Week Webinar January 23, 2008 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Younger Children AND Adolescents Need Immunizations!
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE
More informationHPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge
HPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp
More informationHPV is ubiquitous. Skin-to-Skin Contact. Most will not develop cancer. By age 50, 80% of women will have acquired a genital HPV infection
Worldwide, HPV causes ~5% of all new cancers occurring in males and females annually Globally, HPVs are responsible for: Virtually 100% of cervical cancers 70% of vaginal cancers 43% of vulvar cancers
More informationHPV Vaccination: Myths and Misconceptions
Session III: HPV Surveillance and vaccines Lima, December 1, 2009 HPV Vaccination: Myths and Misconceptions Eduardo L. Franco James McGill Professor Departments of Oncology and Epidemiology & Biostatistics
More informationCERVICAL CANCER VACCINE DEVELOPMENT
Sexual Health for Marian Saville due 30 th November. CERVICAL CANCER VACCINE DEVELOPMENT Ian H Frazer The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba
More informationNew paradigm for prevention of cervical cancer
European Journal of Obstetrics & Gynecology and Reproductive Biology 130 (2007) 25 29 Expert opinion New paradigm for prevention of cervical cancer GlaxoSmithKline has developed a bivalent vaccine, Cervarix
More informationLower Immune Response in HIV- Positive Girls to the Quadrivalent Human Papillomavirus Vaccine
Lower Immune Response in HIV- Positive Girls to the Quadrivalent Human Papillomavirus Vaccine July 17-18, 2015 7 th International Workshop on HIV Pediatrics Vancouver, Canada J. Brophy, A. Bitnun, J. Raboud,
More informationChapter 13: Current findings from prophylactic HPV vaccine trials
Vaccine 24S3 (2006) S3/114 S3/121 Chapter 13: Current findings from prophylactic HPV vaccine trials Laura A. Koutsky a,, Diane M. Harper b a Department of Epidemiology, School of Public Health, University
More informationHPV-Associated Disease and Prevention
HPV-Associated Disease and Prevention Odessa Regional Medical Center May 28, 2015 Erich M. Sturgis, MD, MPH Professor Department of Head & Neck Surgery Department of Epidemiology Christopher & Susan Damico
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2015 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GARDASIL 9 safely and effectively. See full prescribing information for GARDASIL 9. GARDASIL 9 (Human
More informationHPV vaccines. Margaret Stanley Department of Pathology Cambridge
HPV vaccines Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp & Dohme, GlaxoSmithKline, and Sanofi Pasteur
More informationRecommendations for Human Papillomavirus Vaccination Provincial Infectious Diseases Advisory Committee on Immunization
Recommendations for Human Papillomavirus Vaccination Provincial Infectious Diseases Advisory Committee on Immunization June 11, 2012 i This document was prepared for the Provincial Infectious Diseases
More informationSilvia Franceschi Infections and Cancer Epidemiology Group International Agency for Research on Cancer Lyon, France
From epidemiology to cancerpreventing vaccines: the example of HPV Silvia Franceschi Infections and Cancer Epidemiology Group International Agency for Research on Cancer Lyon, France Milan, 19 March 2007
More informationEach dose of GARDASIL 9 is 0.5-mL Administer GARDASIL 9 as follows: (2.1) Age Regimen Schedule 9 through 14 years 2-dose 0, 6 to 12 months*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GARDASIL 9 safely and effectively. See full prescribing information for GARDASIL 9. GARDASIL 9 (Human
More informationHPV Vaccination. Dr. Vivien Tsu PATH. HPV Vaccination 1
HPV Vaccination Dr. Vivien Tsu PATH HPV Vaccination 1 HPV vaccine overview 1 First vaccines to focus on a female cancer. Prepared from virus-like particles (VLPs). VLPs are non-infectious. Two vaccines
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHuman papillomavirus (HPV) infection causes cervical
ORIGINAL STUDIES Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents A Randomized Controlled
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE
More informationGSK Cervical Cancer Vaccine:
GSK Cervical Cancer Vaccine: Overview of Clinical Data Jovelle B. Laoag-Fernandez, M.D., Ph.D., FPOGS Regional Medical Affairs HPV Vaccines GSK Biologicals Asia Pacific, Australasia, China/Hong Kong, Japan
More information1 Cervical Cancer Prevention and Screening: Update 2010 Michael S. Policar, MD, MPH Clinical Professor of Ob, Gyn, and RS UCSF School of Medicine policarm@obgyn.ucsf.edu No commercial disclosures for this
More informationA Short Review on Human Papillomavirus Vaccines
A Short Review on Human Papillomavirus Vaccines KF TAM MRCOG HYS NGAN FRCOG Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong,
More informationHPV, Cancer Genes, and Raising Expectations
HPV, Cancer Genes, and Raising Expectations Douglas R. Lowy Laboratory of Cellular Oncology, Center for Cancer Research National Cancer Institute, National Institutes of Health Keynote Lecture, IFCPC World
More informationSAGE evidence to recommendations framework i
SAGE evidence to recommendations framework i Question: What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old
More informationMake the CASE FOR PHARMACISTS ONLY. Helpful information for talking to parents about HPV vaccination
FOR PHARMACISTS ONLY Make the CASE Helpful information for talking to parents about HPV vaccination Indication GARDASIL 9 is a vaccine indicated in females 9 through 26 years of age for the prevention
More informationBUILDING TRUST, MANAGING RISK: VACCINE CONFIDENCE AND HUMAN PAPILLOMAVIRUS VACCINATION
BUILDING TRUST, MANAGING RISK: VACCINE CONFIDENCE AND HUMAN PAPILLOMAVIRUS VACCINATION Associate Professor Kristine Macartney Deputy Director, National Centre for Immunisation Research & Surveillance www.ncirs.usyd.edu.au
More informationWhy are we reviewing the evidence on HPV immunization of adolescent girls & what are the questions for SAGE today?
Why are we reviewing the evidence on HPV immunization of adolescent girls & what are the questions for SAGE today? Prof Claire-Anne Siegrist SAGE Member 1 Estimated cervical cancer incidence worldwide
More informationQuadrivalent Human Papillomavirus Vaccine
INVITED ARTICLE VACCINES Bruce Gellin and John F. Modlin, Section Editors Quadrivalent Human Papillomavirus Vaccine Eliav Barr and Gretchen Tamms Merck Research Laboratories, West Point, Pennsylvania The
More informationImmunise against HPV
Immunise against HPV (Human Papillomavirus) Helps prevent cancers caused by HPV infection Information for young people and their families and whānau Human papillomavirus (HPV) immunisation helps protect
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE
More informationThe HPV Immunisation Programme in NZ. Chris Millar Senior Advisor Immunisation Ministry of Health
The HPV Immunisation Programme in NZ Chris Millar Senior Advisor Immunisation Ministry of Health chris_millar@moh.govt.nz 4 September 2015 Background of NZ s HPV Immunisation Programme Aim: To protect
More informationPerfecting the Prevention of Cervical cancer. I have no financial interests in any product I will discuss today. Preview
Perfecting the Prevention of Cervical cancer Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests in any
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationThe Importance of HPV Vaccination and Strategies to Increase Uptake in Pediatric & Family Practices
The Importance of HPV Vaccination and Strategies to Increase Uptake in Pediatric & Family Practices Amanda Dempsey, MD, PhD, MPH Associate Professor of Pediatrics Children s Hospital Colorado October,
More informationHPV/Cervical Cancer Resource Guide for patients and providers
DHS: PUBLIC HEALTH DIVISION IMMUNIZATION PROGRAM HPV/Cervical Cancer Resource Guide for patients and providers Independent. Healthy. Safe. Oregon HPV Provider Resource Kit: Table of Contents Provider Information
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationCervical screening. Cytology-based screening programmes
HPV-FASTER: broadening the scope for prevention of HPV-related cancer Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer
More informationAt the completion of this activity, participants will be better able to : 72 years (women) Pseudovirion based vaccines.
At the completion of this activity, participants will be better able to : 1. Assess the potential effect of HPV infection 2. Identify HPV serotypes associated with particular cancers and genital warts
More informationClinical Study Reducing the Health Burden of HPV Infection Through Vaccination
Infectious Diseases in Obstetrics and Gynecology Volume 2006, Article ID 83084, Pages 1 5 DOI 10.1155/IDOG/2006/83084 Clinical Study Reducing the Health Burden of HPV Infection Through Vaccination David
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationHPV Vaccines. What is HPV? Can a vaccine help prevent HPV?
What is HPV? HPV Vaccines HPV is short for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, which is called an HPV type. HPVs are
More informationBaseline HPV 2009: A route to evaluation of the HPV vaccination programme
Baseline HPV 2009: A route to evaluation of the HPV vaccination programme Dr Sam Hibbitts Senior Lecturer in HPV Department of Obstetrics & Gynaecology School of Medicine Cardiff University Avian Papillomavirus
More informationCERVARIX GlaxoSmithKline
CERVARIX GlaxoSmithKline International Data Sheet. Version 2 (31/01/2007) Cervarix 1. Name of the medicinal product CervarixTM Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted).
More informationUp date. sexually transmission HPV HPV HPV. high-risk HPV HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, 68 HPV
Up date Kei Kawana HPV HPV HPV HPV HPV6, 11 HPV HPV HPV vaccine preventable diseasevpd HPV HPV HPV DNA 8 HPV 100 genomic type HPV HPV HPV HPV HPV 1 sexually transmission HPV HPV 2 HPV high-riskhpv HPV16,
More informationQuestions about new changes to the HPV vaccine and vaccination schedule
HPV VACCINES FREQUENTLY ASKED QUESTIONS This fact sheet provides responses to common patient questions and concerns about human papillomavirus (HPV) and the HPV vaccines and vaccination. There is misleading
More informationCervical Cancer The Role of Primary Care in Reducing Cancer Disparities
Cervical Cancer The Role of Primary Care in Reducing Cancer Disparities March 28, 2015 Electra D. Paskett, Ph.D. The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More information